CA
NZ
UK
AU
IND
US
A NASDAQ-listed clinical-stage biopharmaceutical company is trading sharply lower today despite reporting positive clinical data for both of its lead oral obesity candidates, a reaction that runs counter to what would typically be viewed as positive news. Structure Therapeutics (NASDAQ:GPCR) reported that aleniglipron's 72-week …
Novartis (NYSE:NVS) shares are plunging roughly 14%, marking one of the stock's worst single-day declines on record, after the company disclosed that del-desiran (delpacibart etedirsen) failed to meet its primary endpoint in the Phase 3 HARBOR trial for myotonic dystrophy type 1. This marks …
Progyny (NASDAQ:PGNY) shares are trading sharply higher after a research firm raised its price target to $33 from $31 while maintaining its Outperform-equivalent rating, citing the company's newly announced win with CalPERS, the California Public Employees' Retirement System, which selected Progyny as its fertility …
Pharvaris (NASDAQ:PHVS) shares are trading sharply higher after the company announced statistically significant, clinically meaningful topline results from the pivotal Phase 3 CHAPTER-3 study of once-daily deucrictibant XR for the prevention of hereditary angioedema attacks. The trial met its primary endpoint with an 83% …
PROCEPT BioRobotics (NASDAQ:PRCT) shares are tumbling as mounting securities litigation continues to overhang the stock, with multiple law firms racing toward a September 22, 2026 lead plaintiff deadline in a federal class action. PROCEPT is a commercial-stage surgical robotics company focused on developing image-guided …
Roivant Sciences (NASDAQ:ROIV) shares are surging after its Pulmovant subsidiary reported strong Phase 2 PHocus results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, presented at the ERS International Congress. The drug hit its primary endpoint with a placebo-adjusted 56.3% reduction in …
Aktis Oncology (NASDAQ:AKTS) shares are sliding sharply as the stock gives back recent gains, trading down after touching a high near $26.99 earlier in the session onVolumeroughly in line with average. Aktis Oncology is a clinical-stage biotechnology company focused on developing targetedAlpharadiopharmaceutical therapies to …
A NASDAQ-listed biotechnology company is trading sharply lower today, on pace for one of its worst single-day losses since 2001, despite announcing landmark survival data for one of its cancer therapies, an outcome that would typically be read as good news for the stock. …
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) shares ticked higher at last closing. Cartesian is a clinical-stage biotechnology company whose lead asset is a messenger-RNA-engineered cell therapy that does not require chemotherapy preconditioning, being developed for autoimmune disease.
Edwards Lifesciences Corporation (NASDAQ:EW) shares were roughly flat at last closing. Edwards is a global leader in structural heart devices, spanning transcatheter aortic valve replacement, transcatheter mitral and tricuspid therapies, and surgical structural heart.
Please wait processing your request...